The late-breaking data, scheduled for presentation on September 30, 2026, highlights the performance of bempikibart, a fully human anti-IL-7Rα antibody. By blocking IL-7 and TSLP signaling, the therapy aims to re-regulate the adaptive immune system, addressing the underlying pathology of the condition. Arash Mostaghimi of Harvard Medical School will present both an oral session and a poster, detailing efficacy and biomarker results observed during the trial's Part B.
Jodie Morrison, CEO of Q32 Bio, stated that the results reinforce the company's commitment to providing targeted options for the approximately 700,000 Americans living with the disease. Beyond alopecia, the company is evaluating the potential of the bempikibart development program across other autoimmune and inflammatory conditions. Following the formal congress presentations, the company plans to release the data on its corporate website.
Comments (0)
No comments yet. Be the first!